Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ELUT Stock Forecast 2026-2027
$0.92
Current Price
$40.45M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ELUT Price Targets
+446.4%
To High Target of $5.00
+446.4%
To Median Target of $5.00
+446.4%
To Low Target of $5.00
ELUT Price Momentum
-4.2%
1 Week Change
-4.2%
1 Month Change
-55.1%
1 Year Change
+33.3%
Year-to-Date Change
-63.4%
From 52W High of $2.50
+83.0%
From 52W Low of $0.50
📊 TOP ANALYST CALLS
Did ELUT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Elutia is one of their latest high-conviction picks.
Latest ELUT Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, ELUT has a bullish consensus with a median price target of $5.00 (ranging from $5.00 to $5.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.92, the median forecast implies a 446.4% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELUT Analyst Ratings
1
Buy
0
Hold
0
Sell
ELUT Price Target Range
Low
$5.00
Average
$5.00
High
$5.00
Current: $0.92
Latest ELUT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELUT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 10, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $6.00 |
| May 9, 2025 | Lake Street | Buy | Maintains | $N/A | |
| Mar 7, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Nov 15, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Sep 6, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Aug 8, 2024 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Jun 21, 2024 | Lake Street | Buy | Maintains | $N/A | |
| Jun 20, 2024 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Jun 18, 2024 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| May 10, 2024 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Nov 14, 2023 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Sep 28, 2023 | Lake Street | Buy | Initiates | $N/A | |
| Sep 26, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Sep 19, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Aug 15, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| May 12, 2023 | Cantor Fitzgerald | Brandon Folkes | Overweight | Maintains | $10.00 |
| Nov 16, 2022 | Truist Securities | Kaila Krum | Buy | Maintains | $10.00 |
| Nov 15, 2022 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $10.50 |
| Mar 4, 2022 | Cowen & Co. | Josh Jennings | Outperform | Maintains | $13.00 |
| Nov 2, 2020 | Cantor Fitzgerald | Overweight | Initiates | $N/A |
Elutia Inc. (ELUT) Competitors
The following stocks are similar to Elutia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Elutia Inc. (ELUT) Financial Data
Elutia Inc. has a market capitalization of $40.45M with a P/E ratio of 0.7x. The company generates $12.46M in trailing twelve-month revenue with a 400.2% profit margin.
Revenue growth is +5.5% quarter-over-quarter, while maintaining an operating margin of -184.4% and return on equity of +192.9%.
Valuation Metrics
Market Cap
$40.45M
Enterprise Value
$18.30M
P/E Ratio
0.7x
PEG Ratio
0.0x
Price/Sales
3.4x
Growth & Margins
Revenue Growth (YoY)
+5.5%
Gross Margin
+57.9%
Operating Margin
-184.4%
Net Margin
+400.2%
EPS Growth
-48.4%
Financial Health
Cash/Price Ratio
+70.4%
Current Ratio
2.0x
Debt/Equity
18.7x
ROE
+192.9%
ROA
-26.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Elutia Inc. (ELUT) Business Model
About Elutia Inc.
What They Do
Develops drug-eluting biomaterials for healthcare.
Business Model
Elutia Inc. generates revenue by developing and commercializing innovative drug-eluting biomaterials, which deliver active pharmaceutical ingredients directly to target tissues. This targeted approach not only enhances therapeutic efficacy but also reduces systemic side effects, making their products applicable in various medical fields such as wound care, cardiovascular treatments, and orthopedics.
Additional Information
Elutia is positioned at the forefront of precision medicine, leveraging advanced biomaterial technologies to improve patient outcomes and transform traditional therapeutic methods. Their role as an influencer in the healthcare industry emphasizes their commitment to medical innovation and the evolving demands of modern medicine.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
25
CEO
Dr. C. Randal Mills Ph.D.
Country
United States
IPO Year
2020
Website
elutia.comElutia Inc. (ELUT) Latest News & Analysis
Latest News
Quick Summary
Elutia Inc. (Nasdaq: ELUT) will present and hold one-on-one investor meetings at the Planet MicroCap Showcase 2026 on June 17-18 in Las Vegas, featuring CEO Dr. Randy Mills and CSO Dr. Michelle Williams.
Why It Matters
Elutia's CEO and CSO engaging with investors at a major showcase signals potential growth and innovation in drug-eluting technologies, attracting investor interest and possibly influencing stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Elutia Inc. granted equity awards to a new employee on May 13, 2026, under its 2026 Inducement Award Plan, as part of its recruiting efforts.
Why It Matters
Equity awards can signal growth and talent acquisition, suggesting Elutia is investing in its future. This may boost confidence among investors regarding the company's long-term potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Elutia Inc. (ELUT) has released its Q1 2026 earnings call transcript, providing insights into its financial performance and strategic direction for investors.
Why It Matters
The Q1 2026 earnings call for Elutia Inc. provides insights into the company's financial performance, growth prospects, and market positioning, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
NXT-41's FDA review progresses, with new automated manufacturing supporting over 80% gross margin. Company has $36.5M in cash and will hold a conference call today at 5 PM ET.
Why It Matters
Advancements with FDA on NXT-41 and a new manufacturing process indicate strong growth potential. High gross margins, cash reserves, and market demand enhance investment appeal.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Elutia Inc. (Nasdaq: ELUT) will present at the 16th Annual LD Micro Invitational in Los Angeles on May 18, 2026, featuring CEO Dr. Randy Mills and CFO Matt Ferguson.
Why It Matters
Elutia's participation in the LD Micro Invitational signals potential investor interest and strategic updates, which could influence stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Elutia Inc. (NASDAQ: ELUT) will present at the LD Micro Invitational on May 18, 2026, discussing its drug-eluting biomatrix technology for post-surgical infection in breast reconstruction.
Why It Matters
Elutia's presentation highlights its innovative biomatrix technology addressing post-surgical infections, potentially increasing market demand and investor interest in its growth prospects.
Source: Newsfile Corp
Market Sentiment:
Neutral
Frequently Asked Questions About ELUT Stock
What is Elutia Inc.'s (ELUT) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, Elutia Inc. (ELUT) has a median price target of $5.00. The highest price target is $5.00 and the lowest is $5.00.
Is ELUT stock a good investment in 2027?
According to current analyst ratings, ELUT has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELUT stock?
Wall Street analysts predict ELUT stock could reach $5.00 in the next 12 months. This represents a 446.4% increase from the current price of $0.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elutia Inc.'s business model?
Elutia Inc. generates revenue by developing and commercializing innovative drug-eluting biomaterials, which deliver active pharmaceutical ingredients directly to target tissues. This targeted approach not only enhances therapeutic efficacy but also reduces systemic side effects, making their products applicable in various medical fields such as wound care, cardiovascular treatments, and orthopedics.
What is the highest forecasted price for ELUT Elutia Inc.?
The highest price target for ELUT is $5.00 from at , which represents a 446.4% increase from the current price of $0.92.
What is the lowest forecasted price for ELUT Elutia Inc.?
The lowest price target for ELUT is $5.00 from at , which represents a 446.4% increase from the current price of $0.92.
What is the overall ELUT consensus from analysts for Elutia Inc.?
The overall analyst consensus for ELUT is bullish. Out of 6 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are ELUT stock price projections?
Stock price projections, including those for Elutia Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 8:23 AM UTC